Cellular immunotherapy for malignant gliomas

Expert Opinion on Biological Therapy

Volumn 16, Issue 10, 2016, Pages 1265-1275

  Lin, Yi ^a   Okada, Hideho ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adoptive cell transfer; CAR T cell therapy; cellular immunotherapy; dendritic cell vaccine; Glioma

Indexed keywords

CANCER VACCINE; CHIMERIC ANTIGEN RECEPTOR; DENDRITIC CELL VACCINE; MELAN A; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR CELL VACCINE; VIRUS ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CELL ENGINEERING; CELLULAR IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); EFFECTOR CELL; FEASIBILITY STUDY; GAMMA DELTA T LYMPHOCYTE; GLIOBLASTOMA; HUMAN; HUMAN CYTOMEGALOVIRUS; IMAGE ANALYSIS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LONG TERM SURVIVAL; LYMPHOCYTE MIGRATION; LYMPHOKINE ACTIVATED KILLER CELL; NEUROIMAGING; NONHUMAN; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR REGRESSION; ANIMAL; BIOLOGICAL THERAPY; BRAIN NEOPLASMS; DRUG EFFECTS; GLIOMA; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CANCER VACCINES; CELL- AND TISSUE-BASED THERAPY; GLIOMA; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84985906050     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2016.1214266     Document Type: Review

References (118)

1. Q.T.Ostrom, H.Gittleman, J.Fulop, et al. CBTRUS statistical report:primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015 Oct;17 Suppl 4:iv1–iv62. doi:10.1093/neuonc/nov189.
2. R.Stupp, W.P.Mason, M.J.van den Bent, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa043330.
3. F.S.Hodi, S.J.O’Day, D.F.McDermott, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711–723.
4. C.Robert, G.V.Long, B.Brady, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372(4):320–330.
5. C.Robert, A.Ribas, J.D.Wolchok, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma:a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20;384(9948):1109–1117.
6. R.Sundar, B.C.Cho, J.R.Brahmer, et al. Nivolumab in NSCLC:latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar;7(2):85–96. doi:10.1177/1758834014567470.
7. P.W.Kantoff, C.S.Higano, N.D.Shore, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411–422.
8. S.L.Maude, N.Frey, P.A.Shaw, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507–1517.
9. S.A.Grupp, M.Kalos, D.Barrett, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 Apr 18;368(16):1509–1518.
10. D.Dilloo, K.Bacon, W.Holden, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med. 1996 Oct;2(10):1090–1095.
11. H.Okada, F.S.Lieberman, K.A.Walter, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007;5:67. doi:10.1186/1479-5876-5-67.
12. M.Kusumoto, S.Umeda, A.Ikubo, et al. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother. 2001 Sep;50(7):373–381.
13. G.Dranoff, E.Jaffee, A.Lazenby, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993 Apr 15;90(8):3539–3543.
14. A.Dols, J.W.Smith2nd, S.L.Meijer, et al. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line:clinical and immunological results. Hum Gene Ther. 2003 Jul 20;14(11):1117–1123.
15. H.Okada, K.M.Giezeman-Smits, H.Tahara, et al. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther. 1999 Feb;6(2):219–226. doi:10.1038/sj.gt.3300798.
16. H.Okada, L.Villa, J.Attanucci, et al. Cytokine gene therapy of gliomas:effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther. 2001 Aug;8(15):1157–1166. doi:10.1038/sj.gt.3301496.
17. J.Eguchi, K.Hiroishi, S.Ishii, et al. Interleukin-4 gene transduced tumor cells promote a potent tumor-specific Th1-type response in cooperation with interferon-alpha transduction. GeneTher. 2005;12:733–741.
18. N.Kuwashima, F.Nishimura, J.Eguchi, et al. Delivery of dendritic cells engineered to secrete IFN-{alpha} into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines:dependence on apoptotic pathways. J Immunol. 2005;175(4):2730–2740. doi:10.4049/jimmunol.175.4.2730.
19. E.Ishikawa, Y.Muragaki, T.Yamamoto, et al. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. J Neurosurg. 2014 Sep;121(3):543–553. doi:10.3171/2014.5.JNS132392.
20. W.T.CurryJr., R.Gorrepati, M.Piesche, et al. Vaccination with irradiated autologous tumor cells mixed with irradiated GM-K562 cells stimulates antitumor immunity and T lymphocyte activation in patients with recurrent malignant glioma. Clin Cancer Res. 2016 Feb 12;22:2885–2896. doi:10.1158/1078-0432.CCR-15-2163.
21. P.Kalinski, H.Edington, H.J.Zeh, et al. Dendritic cells in cancer immunotherapy:vaccines or autologous transplants? Immunol Res. 2011 Aug;50(2–3):235–247. doi:10.1007/s12026-011-8224-z.
22. D.Ajay, L.Sanchez-Perez, B.D.Choi, et al. Immunotherapy with tumor vaccines for the treatment of malignant gliomas. Curr Drug Discov Technol. 2012 Dec;9(4):237–255.
23. S.De Vleeschouwer, S.W.Van Gool, F.Van Calenbergh Immunotherapy for malignant gliomas:emphasis on strategies of active specific immunotherapy using autologous dendritic cells. Childs Nerv Syst. 2005 Jan;21(1):7–18. doi:10.1007/s00381-004-0994-3.
24. L.M.Liau, K.L.Black, N.A.Martin, et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report Neurosurg Focus. 2000;9(6):e8.
25. J.S.Yu, C.J.Wheeler, P.M.Zeltzer, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001 Feb 1;61(3):842–847.
26. C.J.Wheeler, K.L.Black, G.Liu, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008 Jul 15;68(14):5955–5964.
27. H.Ardon, S.W.Van Gool, T.Verschuere, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma:results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother. 2012 Nov;61(11):2033–2044. doi:10.1007/s00262-012-1261-1.
28. R.M.Prins, H.Soto, V.Konkankit, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011 Mar 15;17(6):1603–1615.
29. H.Okada. Brain tumor immunotherapy with type-1 polarizing strategies. Ann NY Acad Sci. 2009 Sep;1174:18–23. doi:10.1111/j.1749-6632.2009.04932.x.
30. J.H.Sampson, D.A.Mitchell. Vaccination strategies for neuro-oncology. Neuro Oncol. 2015 Nov;17 Suppl 7:vii15–vii25. doi:10.1093/neuonc/nov159.
31. D.A.Reardon, G.Freeman, C.Wu, et al. Immunotherapy advances for glioblastoma. Neuro-oncology. 2014 Nov;16(11):1441–1458. doi:10.1093/neuonc/nou212.
32. D.A.Reardon, K.W.Wucherpfennig, G.Freeman, et al. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun;12(6):597–615. doi:10.1586/erv.13.41.• Excellent review providing an updated and comprehensive information on recent immunotherapy approaches for glioblastomas.
33. H.Okada, P.Kalinski, R.Ueda, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011 January 20;29(3):330–336.
34. S.Phuphanich, C.J.Wheeler, J.D.Rudnick, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013 Jan;62(1):125–135. doi:10.1007/s00262-012-1319-0.
35. C.L.SlingluffJr., G.R.Petroni, G.V.Yamshchikov, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003 Nov 1;21(21):4016–4026.
36. C.J.Wheeler, A.Das, G.Liu, et al. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res. 2004 Aug 15;10(16):5316–5326.
37. O.Bloch, C.A.Crane, Y.Fuks, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma:a phase II, single-arm trial. Neuro Oncol. 2014 Jan;16(2):274–279. doi:10.1093/neuonc/not203.
38. A.J.Litterman, D.M.Zellmer, K.L.Grinnen, et al. Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunology. 2013 Jun 15;190(12):6259–6268. doi:10.4049/jimmunol.1203539.• A very well designed and considerate study evaluating impacts of chemotherapy on vaccine-reactive T cells in preclinical glioma vaccine models.
39. K.Dziurzynski, S.M.Chang, A.B.Heimberger, et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012 March 1;14(3):246–255.
40. C.S.Cobbs, L.Harkins, M.Samanta, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62(12):3347–3350.
41. D.A.Mitchell, K.A.Batich, M.D.Gunn, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015 Mar 19;519(7543):366–369. doi:10.1038/nature14320.• An important clinical study demonstrating the role of vaccine-site conditioning by Tetanus Toxoid.
42. R.E.Merchant, M.D.Ellison, H.F.Young. Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations. J Neurooncol. 1990 Apr;8(2):173–188.
43. E.Ishikawa, S.Takano, T.Ohno, et al. Adoptive cell transfer therapy for malignant gliomas. Adv Exp Med Biol. 2012;746:109–120. doi:10.1007/978-1-4614-3146-6_9.
44. T.M.Law, R.J.Motzer, M.Mazumdar, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995 Sep 1;76(5):824–832.
45. H.Fujisaki, H.Kakuda, N.Shimasaki, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009 May 1;69(9):4010–4017.
46. L.Barkholt, E.Alici, R.Conrad, et al. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients:a phase I clinical study. Immunotherapy. 2009 Sep;1(5):753–764. doi:10.2217/imt.09.47.
47. K.Rezvani, R.H.Rouce. The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol. 2015;6:578. doi:10.3389/fimmu.2015.00578.
48. V.Groh, S.Porcelli, M.Fabbi, et al. Human lymphocytes bearing T cell receptor gamma/delta are phenotypically diverse and evenly distributed throughout the lymphoid system. J Exp Med. 1989 Apr 1;169(4):1277–1294.
49. M.von Lilienfeld-Toal, J.Nattermann, G.Feldmann, et al. Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells. Clin Exp Immunol. 2006 Jun;144(3):528–533. doi:10.1111/j.1365-2249.2006.03078.x.
50. M.Girardi, D.E.Oppenheim, C.R.Steele, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science. 2001 Oct 19;294(5542):605–609.
51. D.C.Deniger, S.N.Maiti, T.Mi, et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res. 2014 Nov 15;20(22):5708–5719.
52. A.J.Nicol, H.Tokuyama, S.R.Mattarollo, et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer. 2011 Sep 6;105(6):778–786.
53. L.S.LambJr. Gammadelta T cells as immune effectors against high-grade gliomas. Immunol Res. 2009;45(1):85–95. doi:10.1007/s12026-009-8114-9.
54. N.L.Bryant, G.Y.Gillespie, R.D.Lopez, et al. Preclinical evaluation of ex vivo expanded/activated gammadelta T cells for immunotherapy of glioblastoma multiforme. J Neurooncol. 2011 Jan;101(2):179–188. doi:10.1007/s11060-010-0245-2.
55. L.Pereboeva, L.Harkins, S.Wong, et al. The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation. Cancer Immunol Immunother. 2015 May;64(5):551–562. doi:10.1007/s00262-015-1662-z.
56. L.S.LambJr., J.Bowersock, A.Dasgupta, et al. Engineered drug resistant gammadelta T cells kill glioblastoma cell lines during a chemotherapy challenge:a strategy for combining chemo- and immunotherapy. PLoS One. 2013;8(1):e51805. doi:10.1371/journal.pone.0051805.
57. S.A.Rosenberg, N.P.Restifo. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015 Apr 3;348(6230):62–68. doi:10.1126/science.aaa4967.•• An updated, comprehensive and insightful review on adoptive cell transfer approach for cancer.
58. S.C.Saris, P.Spiess, D.M.Lieberman, et al. Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg. 1992 Mar;76(3):513–519. doi:10.3171/jns.1992.76.3.0513.
59. K.B.Quattrocchi, C.H.Miller, S.Cush, et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol. 1999;45(2):141–157.
60. I.C.Glitza, C.Haymaker, C.Bernatchez, et al. Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma:a case report. Cancer Immunol Res. 2015 Nov;3(11):1201–1206. doi:10.1158/2326-6066.CIR-15-0071.
61. C.M.Balch, L.B.Riley, Y.J.Bae, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg. 1990 Feb;125(2):200–205.
62. G.E.Plautz, G.H.Barnett, D.W.Miller, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg. 1998 Jul;89(1):42–51. doi:10.3171/jns.1998.89.1.0042.
63. G.E.Plautz, D.W.Miller, G.H.Barnett, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res. 2000 Jun;6(6):2209–2218.
64. R.A.Morgan, M.E.Dudley, J.R.Wunderlich, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126–129. doi:10.1126/science.1129003.
65. T.Stanislawski, R.H.Voss, C.Lotz, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol. 2001 Oct;2(10):962–970. doi:10.1038/ni1001-962.
66. L.A.Johnson, R.A.Morgan, M.E.Dudley, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009 Jul 16;114(3):535–546.
67. S.A.Xue, L.Gao, S.Thomas, et al. Development of a Wilms’ tumor antigen-specific T-cell receptor for clinical trials:engineered patient’s T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica. 2010 Jan;95(1):126–134. doi:10.3324/haematol.2009.006486.
68. S.Okamoto, J.Mineno, H.Ikeda, et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 2009 Dec 1;69(23):9003–9011.
69. C.Govers, Z.Sebestyen, M.Coccoris, et al. T cell receptor gene therapy:strategies for optimizing transgenic TCR pairing. Trends Mol Med. 2010 Feb;16(2):77–87. doi:10.1016/j.molmed.2009.12.004.
70. L.Zhang, R.A.Morgan. Genetic engineering with T cell receptors. Adv Drug Deliv Rev. 2012 Jun 1;64(8):756–762.
71. M.R.Parkhurst, J.C.Yang, R.C.Langan, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011 Mar;19(3):620–626. doi:10.1038/mt.2010.272.
72. R.A.Morgan, N.Chinnasamy, D.Abate-Daga, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunotherapy. 2013 Feb;36(2):133–151. doi:10.1097/CJI.0b013e3182829903.•• A very important report demonstrating the importance of selecting appropriate antigens as well as previously unrecognized levels of susceptibility of the brain to T cell responses.
73. P.F.Robbins, S.H.Kassim, T.L.Tran, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor:long-term follow-up and correlates with response. Clin Cancer Res. 2015 Mar 1;21(5):1019–1027.
74. A.P.Rapoport, E.A.Stadtmauer, G.K.Binder-Scholl, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015 Aug;21(8):914–921. doi:10.1038/nm.3910.
75. M.C.Ngo, C.M.Rooney, J.M.Howard, et al. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet. 2011 April 15;20(R1):R93–R99.
76. M.Moeller, N.M.Haynes, J.A.Trapani, et al. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther. 2004;11(5):371–379. doi:10.1038/sj.cgt.7700710.
77. R.A.Beckman, L.M.Weiner, H.M.Davis. Antibody constructs in cancer therapy - protein engineering strategies to improve exposure in solid tumors. Cancer. 2007 Jan;109(2):170–179. doi:10.1002/cncr.22402.
78. M.Weijtens, R.Willemsen, D.Valerio, et al. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol. 1996 July 15;157(2):836–843.
79. M.V.Maus, C.H.June. Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res. 2016 Apr 15;22(8):1875–1884.
80. K.S.Kahlon, C.Brown, L.J.Cooper, et al. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004 Dec 15;64(24):9160–9166.
81. N.Ahmed, V.S.Salsman, Y.Kew, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010 Jan 15;16(2):474–485.
82. K.K.Chow, S.Naik, S.Kakarla, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2013 Mar;21(3):629–637. doi:10.1038/mt.2012.210.
83. M.Ohno, T.Ohkuri, A.Kosaka, et al. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J Immunother Cancer. 2013;1:21. doi:10.1186/2051-1426-1-21.
84. L.A.Johnson, J.Scholler, T.Ohkuri, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015 Feb 18;7(275):275ra22.
85. S.S.Bullain, A.Sahin, O.Szentirmai, et al. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol. 2009 Sep;94(3):373–382. doi:10.1007/s11060-009-9889-1.
86. R.A.Morgan, J.C.Yang, M.Kitano, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–851. doi:10.1038/mt.2010.24.
87. C.E.Brown, B.Badie, M.E.Barish, et al. Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015 Sep 15;21(18):4062–4072.
88. M.A.Pule, B.Savoldo, G.D.Myers, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors:persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov;14(11):1264–1270. doi:10.1038/nm.1882.
89. M.Hegde, A.Corder, K.K.Chow, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013 Nov;21(11):2087–2101. doi:10.1038/mt.2013.185.
90. C.C.Kloss, M.Condomines, M.Cartellieri, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013 Jan;31(1):71–75. doi:10.1038/nbt.2459.
91. S.Wilkie, M.C.Van Schalkwyk, S.Hobbs, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012 Oct;32(5):1059–1070. doi:10.1007/s10875-012-9689-9.
92. Z.Grada, M.Hegde, T.Byrd, et al. TanCAR:a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2:e105. doi:10.1038/mtna.2013.32.
93. K.Minagawa, X.Zhou, S.Mineishi, et al. Seatbelts in CAR therapy:how safe are CARS? Pharmaceuticals (Basel). 2015;8(2):230–249. doi:10.3390/ph8020230.
94. K.T.Roybal, L.J.Rupp, L.Morsut, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016 Feb 11;164(4):770–779.
95. T.Schumacher, L.Bunse, S.Pusch, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014 Jun 25;512:324–327. doi:10.1038/nature13387.
96. B.J.Cameron, A.B.Gerry, J.Dukes, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013 Aug 7;5(197):197ra03.
97. J.H.Sampson, A.B.Heimberger, G.E.Archer, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010 Nov 1;28(31):4722–4729.
98. G.Kohanbash, H.Okada. Myeloid-derived suppressor cells in gliomas and glioma-development. Immunol Invest. 2012;41(6–7):658–679. doi:10.3109/08820139.2012.689591.
99. H.Okada, L.H.Butterfield, R.L.Hamilton, et al. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with Poly-ICLC. Clin Cancer Res. 2015 Jan 15;21(2):286–294.
100. H.Okada, T.Tsugawa, H.Sato, et al. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res. 2004;64(16):5830–5838. doi:10.1158/0008-5472.CAN-04-0130.
101. I.F.Pollack, R.I.Jakacki, L.H.Butterfield, et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 2014 Jul 1;32(19):2050–2058.
102. M.H.Kershaw, G.Wang, J.A.Westwood, et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 2002 Nov 1;13(16):1971–1980.
103. A.Di Stasi, B.De Angelis, C.M.Rooney, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18;113(25):6392–6402.
104. J.A.Craddock, A.Lu, A.Bear, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct;33(8):780–788. doi:10.1097/CJI.0b013e3181ee6675.
105. E.K.Moon, C.Carpenito, J.Sun, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011 Jul 15;17(14):4719–4730.
106. S.A.Grossman, X.Ye, G.Lesser, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011 Aug 15;17(16):5473–5480.
107. M.Chmielewski, H.Abken. TRUCKs:the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145–1154. doi:10.1517/14712598.2015.1046430.
108. S.P.Kerkar, P.Muranski, A.Kaiser, et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 2010 Sep 1;70(17):6725–6734.
109. L.Zhang, S.P.Kerkar, Z.Yu, et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 2011 Apr;19(4):751–759. doi:10.1038/mt.2010.313.
110. M.Chmielewski, C.Kopecky, A.A.Hombach, et al. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011 Sep 1;71(17):5697–5706.
111. C.M.Bollard, C.Rossig, M.J.Calonge, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002 May 1;99(9):3179–3187.
112. D.Abate-Daga, K.Hanada, J.L.Davis, et al. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood. 2013 Aug 22;122(8):1399–1410.
113. L.B.John, C.Devaud, C.P.Duong, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013 Oct 15;19(20):5636–5646.
114. L.B.John, M.H.Kershaw, P.K.Darcy. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology. 2013 Oct 1;2(10):e26286.
115. H.Okada, I.F.Pollack. Do we need novel radiologic response criteria for brain tumor immunotherapy? Expert Rev Neurother. 2011;11(5):619–622. doi:10.1586/ern.11.49.
116. H.Okada, M.Weller, R.Huang, et al. immunotherapy Response Assessment in Neuro-Oncology (iRANO):a report of the RANO working group. Lancet Oncol. 2015;15:534–542. doi:10.1016/S1470-2045(15)00088-1.• This proposes a novel response criteria specifically designed for immunotherapy of brain tumors.
117. J.D.Wolchok, A.Hoos, S.O’Day, et al. Guidelines for the evaluation of immune therapy activity in solid tumors:immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412–7420.
118. P.Y.Wen, D.R.Macdonald, D.A.Reardon, et al. Updated response assessment criteria for high-grade gliomas:response assessment in neuro-oncology working group. J Clin Oncol. 2010 April 10;28(11):1963–1972.